Almirall SA: Happify Health and Almirall launch a digital solution to support psoriasis patients


Happify Health and Almirall Launch Digital Solution to Support Psoriasis Patients

June 13, 2022

NEW YORK, NY, June 13, 2022 – Today, happy healththe Intelligent Healing Company™, and Almirall S.A.(BME: ALM), a global biopharmaceutical company focused on skin health, announced that Claro, a digital program developed through the two companies’ innovative partnership, is live and now available for people with psoriasis in Spain, Italy and the UK. -United. Claro was designed to improve the mental well-being of people with psoriasis through cognitive behavioral therapy, positive psychology, and mindfulness.

Psoriasis is one of the most common skin diseases in the world, affecting approximately 60 million people worldwide2. A 2019 study in Maedica, a Journal of Clinical Medicine, establishes a clear link between skin psychology and quality of life in people with psoriasis.4.An estimated 20% to 30% of people with moderate to severe psoriasis worldwide also suffer from mental health issues, such as anxiety and depression.1. About 80% of people with psoriasis have mild to moderate symptoms, with direct healthcare costs for psoriasis treatment exceeding $65 billion per year3.

“At Almirall, we are proud to offer patients with psoriasis a wide range of medicines that cover the full spectrum of the disease, from mild to severe. Claro helps us fulfill our commitment to people with psoriasis, by providing them with providing an enhanced solution addressed to their well-being, so they can get their lives back,” said Dr Volker KoscielnyMD, Chief Medical Officer of Almirall.

“Psoriasis is a significant burden in the daily lives of 71% of people who suffer from it, according to the National Psoriasis Foundation in the UK.3“, said Theo Ahadome, Senior Vice President of Marketing at Happify Health. “We are very pleased with the level of engagement we are seeing among Claro users so far, and this partnership gives us the opportunity to to study the effectiveness of digital programs for patients with psoriasis engaged during psoriasis treatment and improving their quality of life.

About Admirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to meet the needs of patients through science to improve their lives. Our Noble Purpose is at the heart of our work: “To transform the world of patients by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and revolutionary medical dermatology products to bring our innovative solutions to patients who need them.

The company, founded in 1943 and based in Barcelona, ​​is listed on the Spanish Stock Exchange and (ticker: ALM). Throughout its 79-year history, Almirall has always focused on patient needs. Currently, Almirall has a direct presence in 21 countries and strategic agreements in more than 70, with approximately 1,800 employees. The total turnover in 2021 was 836.5 million euros.

For more information, visit


1. HL Richards, DG Fortune, CE Griffiths, CJ Main. The contribution of perceptions of stigma to disability in patients with psoriasis. J Psychosom Res., 50 (2001), p. 11-15.

2. Overview of the 2008 National Psoriasis Foundation survey. Available at: PTT-24087-quality-of-life-issues-and-measurement-in-patients-with-psor (

3. EA Dowlatshahi, M. Wakkee, LR Arends, T. Nijsten. The prevalence and likelihood of depressive symptoms and clinical depression in patients with psoriasis: a systematic review and meta-analysis. J Invest Dermatol., 134 (2014), p. 1542-1551.

4. M. Esposito, R. Saraceno, A. Giunta, M. Maccarone, S. Chimenti. An Italian study on psoriasis and depression. Dermatology., 212 (2006), p. 123-127.


Comments are closed.